Back to results
US 11,890,281 B2Granted
SHP2 phosphatase inhibitors and methods of making and using the same
AssigneeRelay Therapeutics, Inc.
InventorsAlexander M. Taylor, André Lescarbeau, Jing Wang, Yanyan Zhang, Gaodeng Lian
Life of this patent
Estimating the term…
Abstract
The disclosure is in part directed to crystalline forms of (R)-1′-(3-(3,4-dihydro-1,5-naphthyridin-1(2H)-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-3H-spiro[benzofuran-2,4′-piperidin]-3-amine, its salt, and variants thereof.
Claims27
A solid form of Compound I-1:
- or a pharmaceutically acceptable salt thereof,
- characterized by an X-ray powder diffraction (XRPD) pattern having at least two peaks, in degrees 2θ, each peak selected from the group consisting of about 24.6, about 19.9, about 16.0, about 6.7, about 12.8, about 13.4, and about 20.7.
A compound of Formula (I)
- wherein,
- m is 1-9;
- n is 1-3;
- and
- X is selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, methane sulfonic acid, phosphoric acid, p-toluene sulfonic acid, benzene sulfonic acid, oxalic acid, L-aspartic acid, maleic acid, malonic acid, L-tartaric acid, fumaric acid, citric acid, succinic acid, and glutaric acid, wherein the compound is in solid form.
2 more elements
A process for preparing a compound of Formula I-1, the process comprising the step of neutralizing a compound of Formula I-3 with NaOH, thereby forming the compound of Formula I-1:
Dependencies are inferred from the claim text.